Pictet Asset Management Holding SA Sells 25,011 Shares of Elevance Health, Inc. $ELV

Pictet Asset Management Holding SA lowered its stake in shares of Elevance Health, Inc. (NYSE:ELV) by 16.2% during the fourth quarter, Holdings Channel reports. The fund owned 129,160 shares of the company’s stock after selling 25,011 shares during the period. Pictet Asset Management Holding SA’s holdings in Elevance Health were worth $45,277,000 at the end of the most recent reporting period.

A number of other hedge funds have also recently added to or reduced their stakes in the stock. Vanguard Group Inc. grew its holdings in Elevance Health by 0.6% during the 3rd quarter. Vanguard Group Inc. now owns 22,998,645 shares of the company’s stock worth $7,431,322,000 after acquiring an additional 141,747 shares during the last quarter. Wellington Management Group LLP grew its holdings in Elevance Health by 4.8% during the 3rd quarter. Wellington Management Group LLP now owns 6,621,297 shares of the company’s stock worth $2,139,473,000 after acquiring an additional 303,099 shares during the last quarter. Artisan Partners Limited Partnership grew its holdings in Elevance Health by 24.5% during the 3rd quarter. Artisan Partners Limited Partnership now owns 4,576,805 shares of the company’s stock worth $1,478,857,000 after acquiring an additional 901,626 shares during the last quarter. First Eagle Investment Management LLC boosted its holdings in Elevance Health by 25.0% in the third quarter. First Eagle Investment Management LLC now owns 3,998,603 shares of the company’s stock valued at $1,292,029,000 after acquiring an additional 798,457 shares during the last quarter. Finally, Invesco Ltd. boosted its holdings in Elevance Health by 22.9% in the third quarter. Invesco Ltd. now owns 2,597,488 shares of the company’s stock valued at $839,300,000 after acquiring an additional 484,303 shares during the last quarter. Institutional investors own 89.24% of the company’s stock.

Analyst Upgrades and Downgrades

ELV has been the topic of several recent research reports. UBS Group set a $400.00 price target on Elevance Health in a report on Thursday, January 29th. Barclays raised their price objective on shares of Elevance Health from $393.00 to $408.00 and gave the company an “overweight” rating in a research note on Friday, April 24th. Citigroup raised shares of Elevance Health to a “buy” rating in a research note on Wednesday. Evercore raised their price target on Elevance Health from $345.00 to $360.00 in a research report on Thursday, April 23rd. Finally, Royal Bank Of Canada lowered Elevance Health from an “outperform” rating to a “sector perform” rating and set a $358.00 price target on the stock. in a research report on Tuesday, February 3rd. Thirteen research analysts have rated the stock with a Buy rating and ten have issued a Hold rating to the stock. Based on data from MarketBeat, the company currently has an average rating of “Moderate Buy” and a consensus target price of $384.58.

Elevance Health Stock Performance

Shares of ELV opened at $376.29 on Thursday. The company has a debt-to-equity ratio of 0.70, a quick ratio of 1.48 and a current ratio of 1.48. Elevance Health, Inc. has a twelve month low of $273.71 and a twelve month high of $424.24. The firm’s 50 day moving average price is $310.12 and its two-hundred day moving average price is $331.59. The firm has a market cap of $81.71 billion, a P/E ratio of 16.01, a PEG ratio of 2.13 and a beta of 0.49.

Elevance Health (NYSE:ELV) last announced its quarterly earnings results on Wednesday, April 22nd. The company reported $12.58 earnings per share for the quarter, beating analysts’ consensus estimates of $10.74 by $1.84. The firm had revenue of $49.49 billion for the quarter, compared to analyst estimates of $48.21 billion. Elevance Health had a net margin of 2.62% and a return on equity of 15.58%. The business’s revenue was up 1.5% on a year-over-year basis. During the same quarter in the previous year, the firm posted $11.97 earnings per share. Elevance Health has set its FY 2026 guidance at 19.850- EPS. On average, analysts forecast that Elevance Health, Inc. will post 26.79 EPS for the current fiscal year.

Elevance Health Announces Dividend

The business also recently announced a quarterly dividend, which will be paid on Thursday, June 25th. Investors of record on Wednesday, June 10th will be issued a dividend of $1.72 per share. This represents a $6.88 annualized dividend and a yield of 1.8%. The ex-dividend date is Wednesday, June 10th. Elevance Health’s dividend payout ratio is presently 29.26%.

Trending Headlines about Elevance Health

Here are the key news stories impacting Elevance Health this week:

• Positive Sentiment: Bank of America upgraded ELV from “neutral” to “buy” and raised its price target to $435 (from $405), signaling renewed conviction and implying meaningful upside versus the current share level. BofA upgrade (TickerReport)
• Positive Sentiment: JPMorgan bumped its price target to $411 and maintained an “overweight” rating, another major shop lifting estimates and supporting the stock. JPMorgan raises PT to $411 (MarketScreener)
• Positive Sentiment: Analysts at multiple outlets upgraded Elevance (and peer Centene) on expectations that Medicaid margins will recover—this reduces near?term reimbursement risk priced into insurers. Analysts upgrade Elevance, Centene (Investing.com)
• Positive Sentiment: Investor and media focus on Elevance’s Q1 earnings call (analyst questions highlight management’s guidance and margin tempo) reinforces confidence in the beat and FY guidance that management provided. 5 must-read analyst questions from Q1 call (MSN)
• Positive Sentiment: Insiders purchased roughly US$3.68M of stock, a bullish signal that insiders are confident in the company’s outlook. Insider buying (Yahoo Finance)
• Neutral Sentiment: Hotchkis & Wiley’s investor letter says ELV is positioned for long?term margin improvement but notes medium?term headwinds; useful context but not a catalyst by itself. Hotchkis & Wiley investor letter summary (InsiderMonkey)
• Neutral Sentiment: Peer earnings (Centene beat and raised outlook; UHS beat) support a healthier healthcare sector narrative, which can buoy ELV sentiment but are indirect drivers. Centene Q1 beat (Zacks) UHS Q1 beat (Zacks)
• Neutral Sentiment: Broader ETF/sector commentary (IHF coverage) mentions providers exposure including ELV but is background rather than company?specific news. IHF ETF piece (Zacks)

About Elevance Health

Elevance Health, Inc (NYSE: ELV) is a large U.S.-based health benefits company that provides a broad range of health insurance products and related services. Headquartered in Indianapolis, the company rebranded from Anthem, Inc to Elevance Health in 2022 while continuing to operate consumer-facing health plans under established state and national brands. Gail Boudreaux serves as chief executive officer and president, leading the company’s strategic focus on integrated health care and benefit delivery.

Elevance’s core activities include offering medical and specialty health plans for individuals, employers and government programs, including Medicare and Medicaid managed-care products.